Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Chetty, from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined advertising practices of websites selling compounded GLP-1 RAs, including semaglutide ...

This syndrome indicates that there is ... The FLOW trial of 3,533 patients is the first primary kidney trial with an incretin mimetic, semaglutide. Like CREDENCE, FLOW was conducted in adults ...

She was prescribed compound semaglutide, a cheaper, custom-made version of the active drug in Ozempic and Wegovy, in May 2022 and lost a staggering 64lbs in six months. But then she made a big ...

Health Canada has issued a recall notice for compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy. The notice was issued on Tuesday ...

The weight loss drug semaglutide was a "miracle" for Staci Rice. Her cravings and "food noise" disappeared, and it help her lose 64 pounds in around eight months. But, even in its cheaper forms ...

Management science gives this problem a name: “Vasa syndrome.” In Sweden ... of 50 government-funded Canadian companies supposedly demonstrating the Canadian auto industry’s ability to manufacture ...

Management science gives this problem a name: “Vasa syndrome.” In Sweden, schoolchildren learn the story of the good ship Vasa, which today has its very own museum in Stockholm. In the 1620s, when ...

But the semaglutide-like drugs also appear to increase the risk ... But there are concerns, as well, including about gastrointestinal and kidney problems, among others. To sort it out, researchers ...

Treatment with once-weekly semaglutide 7.2 mg conferred a 20.7% weight reduction vs. a 17.5% weight loss with semaglutide 2.4 mg. The safety profile of semaglutide 7.2 mg is similar to other GLP-1s.

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under ...